• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

The Greatest Changes and Improvements in HIV Diagnostics Will Be in the Area of Monitoring Disease Progression in Individual Patients

Posted on: Friday, 3 February 2006, 12:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c32105) has announced the addition of HIV Diagnostics: Key Disease Management Role Spells Opportunity to their offering.

HIV stands out as a highly lucrative and expanding market for diagnostics because of the close integration of diagnostics in day-to-day disease diagnosis, management, and drug selection. The greatest changes and improvements in HIV diagnostics will be in the area of monitoring disease progression in individual patients. Such tests will help physicians optimally manage the disease and minimize drug failures and will ultimately have the potential to be incorporated into treatment algorithms.

In this report, Decision Resources review HIV diagnostics in use and in development, the main players involved in the development of novel HIV diagnostics, and the impact these tests will have on HIV drug development in the United States.

Business Implications

-- The HIV diagnostics market is attractive because diagnostics

play an integral role in disease management. Diagnostics are

widely used in initial diagnosis as well as in determining

therapeutic options and monitoring disease progression in

patients. Room remains for development of novel diagnostics

that can aid in better disease management (i.e., help minimize

drug failures and ensure effectiveness of a therapeutic).

-- The markets for HIV screening tests and disease staging tests

have matured to offer several rapid and reliable tests--but

opportunity still awaits novel combination

screening/confirmatory tests that can improve diagnosis rates.

-- Although several tests serve as markers for disease

progression, novel diagnostics that can monitor disease

progression in individual patients and measure clinically

meaningful markers will be widely adopted by physicians to

optimally manage the disease and minimize drug failures.

-- Development of novel diagnostics can help drug developers

identify the most promising agent (a targeted product that

will not be cross-resistant to other classes of ARV drugs and

will achieve clinically meaningful efficacy end points) and

also help select the right target population for clinical

trials.

-- Novel diagnostics such as replication capacity (RC) tests have

the potential to accelerate the drug development process by

providing valuable insight into an agent's activity. FDA

acceptance of a marker identified by new diagnostics as an

efficacy end point will speed drug development--decisions can

be reached earlier about the therapeutic potential of the

agent.

-- The development and commercialization of a rapid, relatively

inexpensive tropism assay will help bring to market a widely

awaited new class of therapeutics: the chemokine receptor

antagonists, which are being touted as the next breakthrough

in HIV therapeutics. Without an associated diagnostic, these

agents will not be able to reach their full market potential.

Contents Include: - Introduction - HIV Pathophysiology - Viral Classification and Co-Receptor Tropism - Resistant HIV - HIV Diagnostics - Screening/Confirmatory Tests - Staging Tests - Resistance Tests - Guidelines for Diagnostics Use - Administration of HIV Diagnostics - Emerging Diagnostic Tests - Select Key Players in HIV Diagnostics - Abbott Laboratories - ViroLogic - Outlook for HIV Diagnostics - Appendix. References Companies mentioned in this report include: - Pfizer - GlaxoSmithKline - Schering-Plough - Progenics - Takeda - Human Genome Sciences - Merck - AnorMed - Sankyo/Kureha - Abbott - BioMerieux - Bio-Rad - Calypte - Coulter - Murex - OraSure Technologies - Waldheim Pharmazeutika - MedMira - Bayer Nucleic Acid Diagnostics - Roche - Virco - PerkinElmer

For more information visit http://www.researchandmarkets.com/reports/c32105 Decision Resources

Source: Business Wire

More News in this Category